A subset of signal transduction pathways is required for hippocampal growth cone collapse induced by ephrin-A5

Developmental Neurobiology

Volumn 68, Issue 10, 2008, Pages 1269-1286

  Yue, Xin ^a,b   Dreyfus, Cheryl ^b   Kong, Tony Ah Ng ^a   Zhou, Renping ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

cGMP dependent protein kinase; Eph family; Ephrins; Erk; Growth cone collapse; Myosin light chain kinase; Phosphotyrosine phosphatase

Indexed keywords

B RAF KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; EPHRIN A5; EPHRIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYOSIN LIGHT CHAIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH CONE; HIPPOCAMPUS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLIC GMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; EPHRIN-A5; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GROWTH CONES; HIPPOCAMPUS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 1; MYOSIN-LIGHT-CHAIN KINASE; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS B-RAF; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 49049112432     PISSN: 00223034     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/dneu.20657     Document Type: Article

References (96)

1. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, et al. 1999. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13:295-306.
2. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, et al. 1996. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271:20246-20249.
3. Andres AC, Ziemiecki A. 2003. Eph and ephrin signaling in mammary gland morphogenesis and cancer. J Mammary Gland Biol Neoplasia 8:475-485.
4. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, et al. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949.
5. Becker E, Huynh-Do U, Holland S, Pawson T, Daniel TO, Skolnik EY. 2000. Nck-interacting Ste20 kinase couples Eph receptors to c-Jun N-terminal kinase and integrin activation. Mol Cell Biol 20:1537-1545.
6. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686.
7. Butt E, van Bemmelen M, Fischer L, Walter U, Jastorff B. 1990. Inhibition of cGMP-dependent protein kinase by (Rp)-guanosine 3′,5′- monophosphorothioates. FEBS Lett 263:47-50.
8. Campbell DS, Holt CE. 2003. Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. Neuron 37:939-952.
9. Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, Bussell KN, et al. 2003. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5:445-456.
10. Compagni A, Logan M, Klein R, Adams RH. 2003. Control of skeletal patterning by ephrinB1-EphB interactions. Dev Cell 5:217-230.
11. Cowan CW, Shao YR, Sahin M, Shamah SM, Lin MZ, Greer PL, Gao S, et al. 2005. Vav family GEFs link activated Ephs to endocytosis and axon guidance [see comment]. Neuron 46:205-217.
12. Dail M, Richter M, Godement P, Pasquale EB. 2006. Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion. J Cell Sci 119:1244-1254.
13. Davis S, Gale NW, Aldrich TH, Maisonpierre PC, Lhotak V, Pawson T, Goldfarb M, et al. 1994. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266:816-819.
14. Davy A, Aubin J, Soriano P. 2004. Ephrin-B1 forward and reverse signaling are required during mouse development. Genes Dev 18:572-583.
15. Dhawan P, Singh AB, Ellis DL, Richmond A. 2002. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62:7335-7342.
16. Dontchev VD, Letourneau PC. 2002. Nerve growth factor and semaphorin 3A signaling pathways interact in regulating sensory neuronal growth cone motility. J Neurosci 22:6659-6669.
17. Dostmann WR, Taylor SS, Genieser HG, Jastorff B, Doskeland SO, Ogreid D. 1990. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem 265:10484-10491.
18. Elowe S, Holland SJ, Kulkarni S, Pawson T. 2001. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol 21:7429-7441.
19. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632.
20. Flanagan JG, Vanderhaeghen P. 1998. The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21:309-345.
21. Fu WY, Chen Y, Sahin M, Zhao XS, Shi L, Bikoff JB, Lai KO, et al. 2007. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin 1-dependent mechanism. Nat Neurosci 10:67-76.
22. Gallo G, Pollack ED. 1997. Temporal regulation of growth cone lamellar protrusion and the influence of target tissue. J Neurobiol 33:929-944.
23. Gallo G, Yee HF Jr, Letourneau PC. 2002. Actin turnover is required to prevent axon retraction driven by endogenous actomyosin contractility. J Cell Biol 158:1219-1228.
24. Guirland C, Buck KB, Gibney JA, DiCicco-Bloom E, Zheng JQ. 2003. Direct cAMP signaling through G-protein-coupled receptors mediates growth cone attraction induced by pituitary adenylate cyclase-activating polypeptide. J Neurosci 23:2274-2283.
25. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, et al. 2001. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73-81.
26. 2+ signals. Trends Cell Biol 14:320-330.
27. Heroult M, Schaffner F, Augustin HG. 2006. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312:642-650.
28. Hofmann F, Ammendola A, Schlossmann J. 2000. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113 (Part 10):1671-1676.
29. Huynh-Do U, Stein E, Lane AA, Liu H, Cerretti DP, Daniel TO. 1999. Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J 18:2165-2173.
30. Igarashi M, Komiya Y. 1991. Subtypes of protein kinase C in isolated nerve growth cones: Only type II is associated with the membrane skeleton from growth cones. Biochem Biophys Res Commun 178:751-757.
31. Ivanov AI, Romanovsky AA. 2006. Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life 58:389-394.
32. Jaaro H, Rubinfeld H, Hanoch T, Seger R. 1997. Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc Natl Acad Sci USA 94:3742-3747.
33. Kaibuchi K, Kuroda S, Amano M. 1999. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68:459-486.
34. Kao HT, Song HJ, Porton B, Ming GL, Hoh J, Abraham M, Czernik AJ, et al. 2002. A protein kinase A-dependent molecular switch in synapsins regulates neurite outgrowth. Nat Neurosci 5:431-437.
35. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. 2003. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett 537:47-52.
36. Klein R. 2004. Eph/Ephrin signaling in morphogenesis, neural development and plasticity. Curr Opin Cell Biol 16:580-589.
37. Knoll B, Drescher U. 2004. Src family kinases are involved in EphA receptor-mediated retinal axon guidance. J Neurosci 24:6248-6257.
38. Kohda Y, Gemba M. 2001. Modulation by cyclic AMP and phorbol myristate acetate of cephaloridine-induced injury in rat renal cortical slices. Jpn J Pharmacol 85:54-59.
39. Kullander K, Klein R. 2002. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475-486.
40. Lohof AM, Quillan M, Dan Y, Poo MM. 1992. Asymmetric modulation of cytosolic cAMP activity induces growth cone turning. J Neurosci 12:1253-1261.
41. Lukas TJ, Mirzoeva S, Slomczynska U, Watterson DM. 1999. Identification of novel classes of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. J Med Chem 42:910-919.
42. Luo L. 2002. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu Rev Cell Dev Biol 18:601-635.
43. Mann F, Miranda E, Weinl C, Harmer E, Holt CE. 2003. B-type Eph receptors and ephrins induce growth cone collapse through distinct intracellular pathways. J Neurobiol 57:323-336.
44. Matsumoto H, Sasaki Y. 1989. Staurosporine, a protein kinase C inhibitor interferes with proliferation of arterial smooth muscle cells. Biochem Biophys Res Commun 158:105-109.
45. McLaughlin T, O'Leary DD. 2005. Molecular gradients and development of retinotopic maps. Annu Rev Neurosci 28:327-355.
46. Miao H, Burnett E, Kinch M, Simon E, Wang B. 2000. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2:62-69.
47. Miao H, Strebhardt K, Pasquale EB, Shen TL, Guan JL, Wang B. 2005. Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem 280:923-932.
48. Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, et al. 2001. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3:527-530.
49. Mikule K, Sunpaweravong S, Gatlin JC, Pfenninger KH. 2003. Eicosanoid activation of protein kinase C epsilon: Involvement in growth cone repellent signaling. J Biol Chem 278:21168-21177.
50. Ming GL, Song HJ, Berninger B, Holt CE, Tessier-Lavigne M, Poo MM. 1997. cAMP-dependent growth cone guidance by netrin-1. Neuron 19:1225-1235.
51. Nishiyama M, Hoshino A, Tsai L, Henley JR, Goshima Y, Tessier-Lavigne M, Poo MM, et al. 2003. Cyclic AMP/GMP-dependent modulation of Ca2+ channels sets the polarity of nerve growth-cone turning. Nature 423:990-995.
52. Ogita H, Kunimoto S, Kamioka Y, Sawa H, Masuda M, Mochizuki N. 2003. EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in vascular smooth muscle cells. Circ Res 93:23-31.
53. Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H, Watanabe D, et al. 2006. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 168:331-339.
54. Pabbisetty KB, Yue X, Li C, Himanen JP, Zhou R, Nikolov DB, Hu L. 2007. Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: Correlation to function in a growth cone collapse assay. Protein Sci 16:355-361.
55. Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G, Chiarugi P. 2005. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 280:34008-34018.
56. Pasquale EB. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133:38-52.
57. Piper M, Anderson R, Dwivedy A, Weinl C, van Horck F, Leung KM, Cogill E, et al. 2006. Signaling mechanisms underlying Slit2-induced collapse of Xenopus retinal growth cones. Neuron 49:215-228.
58. Poliakov A, Cotrina M, Wilkinson DG. 2004. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 7:465-480.
59. Pratt RL, Kinch MS. 2002. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 21:7690-7699.
60. Ruegg UT, Burgess GM. 1989. Staurosporine. K-252 and UCN-01: Potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 10:218-220.
61. Sahin M, Greer PL, Lin MZ, Poucher H, Eberhart J, Schmidt S, Wright TM, et al. 2005. Eph-dependent tyrosine phosphorylation of ephexin1 modulates growth cone collapse [see comment]. Neuron 46:191-204.
62. Sanders LC, Matsumura F, Bokoch GM, de Lanerolle P. 1999. Inhibition of myosin light chain kinase by p21-activated kinase. Science 283:2083-2085.
63. Seargeant LE, Stinson RA. 1979. Inhibition of human alkaline phosphatases by vanadate. Biochem J 181:247-250.
64. Shamah SM, Lin MZ, Goldberg JL, Estrach S, Sahin M, Hu L, Bazalakova M, et al. 2001. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell 105:233-244.
65. Shintani T, Ihara M, Sakuta H, Takahashi H, Watakabe I, Noda M. 2006. Eph receptors are negatively controlled by protein tyrosine phosphatase receptor type O. Nat Neurosci 9:761-769.
66. Shotelersuk V, Siriwan P, Ausavarat S. 2006. A novel mutation in EFNB1, probably with a dominant negative effect, underlying craniofrontonasal syndrome. Cleft Palate Craniofac J 43:152-154.
67. Silveira LA, Smith JL, Tan JL, Spudich JA. 1998. MLCK-A, an unconventional myosin light chain kinase from Dictyostelium, is activated by a cGMP-dependent pathway. Proc Natl Acad Sci USA 95:13000-13005.
68. Song H, Ming G, He Z, Lehmann M, McKerracher L, Tessier-Lavigne M, Poo M. 1998. Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides. Science 281:1515-1518.
69. Song HJ, Ming GL, Poo MM. 1997. cAMP-induced switching in turning direction of nerve growth cones. Nature 388:275-279.
70. Stein E, Huynh-Do U, Lane AA, Cerretti DP, Daniel TO. 1998. Nek recruitment to Eph receptor, Eph B1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem 273:1303-1308.
71. Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. 1998. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 12:667-678.
72. Surawska H, Ma PC, Salgia R. 2004. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15:419-433.
73. Swiercz JM, Kuner R, Behrens J, Offermanns S. 2002. Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 35:51-63.
74. Takuma T, Ichida T. 1991. Cyclic AMP antagonist Rp-cAMPS inhibits amylase exocytosis from saponin-permeabilized parotid acini. J Biochem 110:292-294.
75. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. 1986. Staurosporine: A potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun 135:397-402.
76. Tang FY, Chiang EP, Shih CJ. 2007. Green tea catechin inhibits ephrin-A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J Nutr Biochem 18:391-399.
77. Tong J, Elowe S, Nash P, Pawson T. 2003. Manipulation of EphB2 regulatory motifs and SH2 binding sites switches MAPK signaling and biological activity. J Biol Chem 278:6111-6119.
78. Twigg SR, Matsumoto K, Kidd AM, Goriely A, Taylor IB, Fisher RB, Hoogeboom AJ, et al. 2006. The origin of EFNB1 mutations in craniofrontonasal syndrome: Frequent somatic mosaicism and explanation of the paucity of carrier males. Am J Hum Genet 78:999-1010.
79. Ueda K, Murata-Hori M, Tatsuka M, Hosoya H. 2002. Rho-kinase contributes to diphosphorylation of myosin II regulatory light chain in nonmuscle cells. Oncogene 21:5852-5860.
80. Vasudevan PC, Twigg SR, Mulliken JB, Cook JA, Quarrell OW, Wilkie AO. 2006. Expanding the phenotype of craniofrontonasal syndrome: Two unrelated boys with EFNB1 mutations and congenital diaphragmatic hernia. Eur J Hum Genet 14:884-887.
81. Vihanto MM, Vindis C, Djonov V, Cerretti DP, Huynh-Do U. 2006. Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor tyrosine kinase. J Cell Sci 119:2299-2309.
82. Vindis C, Cerretti DP, Daniel TO, Huynh-Do U. 2003. EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote Chemotaxis. J Cell Biol 162:661-671.
83. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
84. Wahl S, Barth H, Ciossek T, Aktories K, Mueller BK. 2000. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol 149:263-270.
85. Wang HU, Chen ZF, Anderson DJ. 1998. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741-753.
86. Wen Z, Zheng JQ. 2006. Directional guidance of nerve growth cones. Curr Opin Neurobiol 16:52-58.
87. Wieacker P, Wieland I. 2005. Clinical and genetic aspects of craniofrontonasal syndrome: Towards resolving a genetic paradox. Mol Genet Metab 86:110-116.
88. Wilkinson DG. 2000. Eph receptors and ephrins: Regulators of guidance and assembly. Int Rev Cytol 196:177-244.
89. Wimmer-Kleikamp SH, Lackmann M. 2005. Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB Life 57:421-431.
90. Wipf P, Halter RJ. 2005. Chemistry and biology of wortmannin. Org Biomol Chem 3:2053-2061.
91. Wong EV, Kerner JA, Jay DG. 2004. Convergent and divergent signaling mechanisms of growth cone collapse by ephrinA5 and slit2. J Neurobiol 59:66-81.
92. Xiang Y, Li Y, Zhang Z, Cui K, Wang S, Yuan XB, Wu CP, et al. 2002. Nerve growth cone guidance mediated by G protein-coupled receptors. Nat Neurosci 5:843-848.
93. Yanagihara N, Tachikawa E, Izumi F, Yasugawa S, Yamamoto H, Miyamoto E. 1991. Staurosporine: An effective inhibitor for Ca2+/calmodulin-dependent protein kinase II. J Neurochem 56:294-298.
94. Zhang J, Hughes S. 2006. Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208:453-461.
95. Zheng JQ, Felder M, Connor JA, Poo MM. 1994. Turning of nerve growth cones induced by neurotransmitters. Nature 368:140-144.
96. Zhou R. 1998. The Eph family receptors and ligands. Pharmacol Ther 77:151-181.